Epigenomics is a molecular diagnostics company focusing on the development and commercialization of in vitro diagnostic tests for cancer. Its cancer diagnostic tests aim at finding cancer at early stages before symptoms occur and are carried out conveniently on body fluids such as blood plasma. These tests potentially address millions of individuals in each of the major markets such as the United States, Europe, and Japan and provide product opportunities each with peak sales potentials of several hundred millions of euros for diagnostics companies worldwide. Its lead test development program is in colorectal cancer. Further test are in development for lung and prostate cancer. Each of its products in development addresses either mass markets or high-value niches. While some of them lend themselves to partnering with established diagnostics industry players, others can be commercialized effectively by Epigenomics itself. The concept of its diagnostic tests in development relies on detecting differences in DNA methylation patterns between healthy and sick individuals or between subgroups of patients for disease classification.

As of January 6, 2009, Genelabs Technologies Inc. was acquired by SmithKline Beecham Corporation. Genelabs Technologies, Inc., a biopharmaceutical company, engages in the discovery and development of infectious disease therapies to improve human health. The company's product pipeline consists of infectious disease projects focusing on Hepatitis C virus infection; and late-stage clinical assets, including an investigational vaccine for hepatitis E virus that is being developed by GlaxoSmithKline; and Prestara, an investigational drug for systemic lupus erythematosus. It has license and collaboration agreement with the Novartis Institutes for BioMedical Research for HCV polymerase non-nucleoside discovery research. Genelabs Technologies also has a collaborative research agreement with the National Health Research Institutes and Genovate Biotechnology Co., Ltd. to discover and develop compounds that target the hepatitis C virus. The company was founded in 1983 and is headquartered in Redwood City, California.

EUROIMMUN AG develops and manufactures medical laboratory reagents for the diagnosis of autoimmune and infectious diseases and allergies. It offers indications for autoimmunity, infections, allergology, antigen detection, and molecular diagnostics; autoimmunity products for rheumatology, hepatology, gastroenterology, endocrinology, neurology, nephrology, dermatology, and infertility; and infection products for immunity determination, CSF diagnostics, emerging viruses, avidity, BIOCHIP Mosaics for infectious serology, and others, as well as additional reagents for determination of acute infections.

Immune Disease Institute, Inc. provides biomedical research services. It engages in doing fundamental research to improve human health, harness inflammation, and strengthen immune defense. The company was founded on January 19, 1953 and is headquartered in Boston, MA.

The Brazilian Agricultural Research Corporation (Embrapa) was founded on April 26, 1973, and is under the aegis of the Brazilian Ministry of Agriculture, Livestock, and Food Supply. Since our foundation, and with our partners from the National Agricultural Research System, we have taken on the challenge to develop a genuinely Brazilian model of tropical agriculture and livestock to overcome the barriers that limited the production of food, fiber, and fuel in our country. This effort has helped to change Brazil. Nowadays, our agriculture is one of the most efficient and sustainable ones in the planet. We have incorporated a wide area of formerly degraded Cerrado lands into our production systems; a region that now accounts for nearly 50% of our grain production. We have quadrupled the beef and pork supply and increased the chicken supply 22-fold. These are some of the achievements that took the country from the condition of basic food importer to one of the world's largest food producers and exporters.

Hanwha Chemical Co., Ltd., a subsidiary of Hanwha Corp., is a company headquartered in the South Korea that manufactures chemical products.

Quest Diagnostics Investments LLC, a subsidiary of Quest Diagnostics, Inc., is an American company specializing in medical laboratories.

Manufactures automotive parts, components and related products and accessories

National Cancer Center Korea is a South Korean company located in Goyang-si and ultimately controlled by the Government of South Korea. The firm provides clinical and medical research services.

Hangzhou Kebaite Filter Equipment Co., Ltd., established on 2003-02-18, Business scope includes production,Sales:Liquid Filtration Membrane Material,plastic products,filter element,Plastic film products,Stainless Steel Products,Electrical and Mechanical Equipment,Gas Filtration Membrane Material,Metal filter materials and products,stainless steel filter,Stainless steel complete system and pressure vessel,Wastewater Treatment Equipment,Exhaust gas treatment equipment,water treatment equipment,Activated carbon fiber felt,filter paper,Fluoroplastic anticorrosion equipment for chemicals,industrial container;Product-related technical services;Import and export business of goods and technology**(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Clinical Genomics Pty Ltd. develops and delivers healthcare products for early detection and prevention of disease. The company is headquartered in North Ryde, Australia.

Nippon Corporation engages in flour milling, food materials, processed foods, frozen foods, ready-made meals, and overseas business. They provide wheat flour, wheat bran, warehousing, and port transportation. Their food premixes include corn, rice flour, retail wheat flour, pasta, pasta sauces, olive oil, flax seed, dried noodles, frozen ingredients, and frozen food products.

Zhejiang Oasis Biotechnology Co., Ltd., established on 2021-05-28, Business scope includes general items:Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Sales of Class I Medical Devices;Sales of Class II Medical Devices;Natural science research and experimental development;Experimental analysis instrument sales;Manufacturing of Specialty Chemical Products(Free of Hazardous Chemicals);Specialty Chemicals Sales(Free of Hazardous Chemicals);Import and export;Technology Import and Export;Biochemical product technology research and development;Manufacturing of experimental analysis instruments(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license).licensed items:Class III medical device business(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results).

Rohm and Haas Company is a manufacturer of speciality chemicals for end use markets such as building and construction, electronic devices, packaging, household and personal care products. Headquartered in Philadelphia, the company is organised into three business groups of Specialty Materials, Performance Materials and Electronic Materials, and also has two stand-alone businesses of Powder Coatings and Salt. Formerly a Fortune 500 Company, Rohm and Haas employs more than 17,000 people in 27 countries, with its last sales revenue reported as an independent company at US$8.9 billion. Dow Chemical Company bought Rohm and Haas for $15 billion in 2009.

Eisai R&D Management Co., Ltd., a subsidiary of Eisai Co., Ltd., is a company headquartered in Bunkyo, Japan. The firm engages in research and development of pharmaceuticals.